The impact of electrical charge on the viability and physiology of dendritic cells

被引:22
作者
Hilpert, F
Heiser, A
Wieckhorst, W
Arnold, N
Kabelitz, D
Jonat, W
Pfisterer, J
机构
[1] Univ Klinikum Schleswig Holstein, Klin Gynakol & Geburtshilfe, D-24105 Kiel, Germany
[2] Univ Klinikum Schleswig Holstein, Inst Immunol, D-24105 Kiel, Germany
关键词
D O I
10.1111/j.1365-3083.2005.01677.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 [免疫学];
摘要
The use of electrical charge for electroporation or electrofusion is widely applied to customize dendritic cells (DC) and their immunological properties as anticancer vaccines. The aim of this study was to evaluate the influence of various electrical field strengths on the recovery, viability and physiology of DC. Immature DC were transferred into low-conductive medium and electrically charged within a range of 0-1500 V/cm. Viability was assessed by Trypan Blue dye exclusion or staining with impermeant nucleic acid stains and fluorescence-activated cell sorter analysis. Additionally, apoptosis was determined by flow cytometry after staining with Annexin-V, endocytosis by uptake of fluorescein isothiocyanate-dextran and metabolic activity by a standardized fluorescent live/dead assay. There was a strong correlation between the electrical field strength and the viability and physiology of DC. Field strengths >= 1000 V/cm significantly impaired viability, metabolism and endocytotic activity. Dual fluorescence with 7-7-amino-actinomycin D and Annexin-V demonstrated that loss of viability was predominantly due to necrosis rather than apoptosis. Field strengths <= 500 V/cm allowed to maintain good cell viability and recovery of DC and did not cause alterations of metabolism and endocytosis. Therefore, the frequently used amplification of field strengths to improve the efficacy of electroporation and electrofusion requires critical re-evaluation.
引用
收藏
页码:399 / 406
页数:8
相关论文
共 32 条
[1]
Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo [J].
Boczkowski, D ;
Nair, SK ;
Snyder, D ;
Gilboa, E .
JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 184 (02) :465-472
[2]
Bonehill A, 2003, CANCER RES, V63, P5587
[3]
A method for the production of cryopreserved aliquots of antigen-preloaded, mature dendritic cells ready for clinical use [J].
Feuerstein, B ;
Berger, TG ;
Maczek, C ;
Röder, C ;
Schreiner, D ;
Hirsch, U ;
Haendle, I ;
Leisgang, W ;
Glaser, A ;
Kuss, O ;
Diepgen, TL ;
Schuler, G ;
Schuler-Thurner, B .
JOURNAL OF IMMUNOLOGICAL METHODS, 2000, 245 (1-2) :15-29
[4]
Gottfried Eva, 2002, Cancer Immun, V2, P15
[5]
Annexin V staining due to loss of membrane asymmetry can be reversible and precede commitment to apoptotic death [J].
Hammill, AK ;
Uhr, JW ;
Scheuermann, RH .
EXPERIMENTAL CELL RESEARCH, 1999, 251 (01) :16-21
[6]
Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro [J].
Heiser, A ;
Dahm, P ;
Yancey, DR ;
Maurice, MA ;
Boczkowski, D ;
Nair, SK ;
Gilboa, E ;
Vieweg, J .
JOURNAL OF IMMUNOLOGY, 2000, 164 (10) :5508-5514
[7]
Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells [J].
Hsu, FJ ;
Benike, C ;
Fagnoni, F ;
Liles, TM ;
Czerwinski, D ;
Taidi, B ;
Engleman, EG ;
Levy, R .
NATURE MEDICINE, 1996, 2 (01) :52-58
[8]
Cell fusion: an approach to generating constitutively proliferating human tumor antigen-presenting cells [J].
Jantscheff, P ;
Spagnoli, G ;
Zajac, P ;
Rochlitz, CF .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2002, 51 (07) :367-375
[9]
Electrofusion of syngeneic dendritic cells and tumor generates potent therapeutic vaccine [J].
Kjaergaard, J ;
Shimizu, K ;
Shu, S .
CELLULAR IMMUNOLOGY, 2003, 225 (02) :65-74
[10]
KWANGWOON K, 2004, CANCER IMMUNOL IMMUN, V53, P315